FIELD: medicine; cardiology.
SUBSTANCE: pharmaceutical composition contains agonist A2A receptor and at least, one base oil, and, at least, one cosolvent.
EFFECT: fast and maximum coronary vasodilatation in mammals without invoking related peripheral vasodilatation, elimination of multiple introduction.
26 cl, 8 ex, 3 tbl, 18 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND COMPOSITIONS IMPROVING PATIENT'S TOLERANCE OF MYOCARDIAL VISUALISATION TECHNIQUE | 2007 |
|
RU2459626C2 |
| METHODS OF HEARTBEAT FREQUENCY REDUCTION INCLUDING ADMINISTRATION OF ADENOSINE A RECEPTOR AGONIST TOGETHER WITH BETA-BLOCKER, CALCIUM CANAL BLOCKER OR CARDIAC GLYCOSIDE | 2003 |
|
RU2332220C2 |
| DERIVATIVES OF 2-ALKYNYLADENOSINE USED FOR CONTROL INFLAMMATORY RESPONSE | 2000 |
|
RU2258071C2 |
| METHOD OF PRODUCING A-ADENOSINE RECEPTOR AGONIST AND POLYMORPHS THEREOF | 2007 |
|
RU2447081C2 |
| DERIVATIVES OF BENZOTHIAZOLE AS ADENOSINE RECEPTOR LIGANDS AND MEDICINAL AGENT | 2002 |
|
RU2295523C2 |
| STABLE CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION | 2020 |
|
RU2839656C1 |
| AGONISTS OF ADENOSINE A3-RECEPTORS | 2002 |
|
RU2298557C2 |
| TRANSDERMAL PHARMACEUTICAL COMPOSITIONS CONTAINING ACTIVE AGENTS | 2010 |
|
RU2639087C2 |
| PARTIAL AND FULL AGONISTS OF ADENOSINE RECEPTORS A | 2003 |
|
RU2340623C2 |
| DERIVATIVES OF ADENOSINE, PHARMACEUTICAL COMPOSITION AND METHOD OF CORRECTION OF ELECTRIC DISORDER IN MAMMAL HEART | 1997 |
|
RU2172320C2 |
